ADVFN - Advanced Financial Network.
HOME» NYSE » C » CVS Stock Price » CVS Stock News

Cvs Share News

 Cvs Caremark Corp. Stock Price
CVS Stock Price
 Cvs Caremark Corp. Stock Chart
CVS Stock Chart
 Cvs Caremark Corp. Stock News
CVS Stock News
 Cvs Caremark Corp. Company Information
CVS Company Information
 Cvs Caremark Corp. Stock Trades
CVS Stock Trades

CVS Caremark CEO Merlo's 2011 Pay Jumped 29% To $14.1 Million

By John Kell Of DOW JONES NEWSWIRES NEW YORK -(Dow Jones)- Total pay for CVS Caremark Corp.'s (CVS) chief executive and president, Larry J. Merlo, grew 29% to $14.1 million last year, according to a filing with the Securities and Exchange Commission. The drugstore retailer and pharmacy-benefits manager disclosed that Merlo's base salary, option awards and nonequity incentive-plan compensation all increased, while stock awards were lower. Merlo first joined the company in 1998 and has served in several executive roles, including chief operating officer and president of CVS/pharmacy. He took on his current roles a year ago. Chief Financial Officer Dave Denton's total pay jumped 35% to $4.6 million. Denton has been with CVS since 1999. Per Lofberg, president of CVS Caremark Pharmacy Services, saw his pay decline 55% to $7.1 million, as he joined CVS at the beginning of 2010 and was thus awarded a $1.5 million bonus and $7 million in stock awards during the prior-year period. President of CVS/pharmacy, Mark Cosby, joined CVS last September and was compensated $9.6 million last year. That figure includes a nearly $1.4 million bonus and over $7 million in stock and option awards. CVS's shares ended last year with a 17% gain, exceeding the broader market's growth as investors and analysts praised the company's integration of pharmacy-benefits manager Caremark. CVS has touted the success of its MinuteClinic retail health-care centers, and observers are banking on the retailer to benefit from the contract expiration between rival Walgreen Co. (WAG) and PBM Express Scripts Inc. (ESRX). CVS shares closed down 0.5% to $44.88 and were flat after hours. The stock is up 10% this year. -By John Kell, Dow Jones Newswires; 212-416-2480; john.kell@dowjones.com

Stock News for Cvs (CVS)
DateTimeHeadline
08/31/201612:00:00CVS Health To Present At The Morgan Stanley Global Healthcare...
08/29/201615:23:00Walgreens Forms Alliance With Prime Therapeutics -- Update
08/24/201607:00:00CVS Health and Easterseals Celebrate Ten Years of Partnership...
08/22/201608:30:00CVS Health Research Institute Study Shows Value in Tailoring...
08/18/201612:41:00CVS Health and the CVS Health Foundation Announce $100K Donation...
08/17/201609:30:00CVS Health Makes Overdose-Reversal Drug Available Without A Prescription...
08/16/201608:30:00CVS Health Survey Reveals Two in Five Americans Make Multiple...
08/12/201609:30:00CVS Health Makes Overdose-Reversal Drug Naloxone Available Without...
08/11/201608:30:00CVS Pharmacy Launches Breakthrough, End-to-End Mobile Payment...
08/05/201614:50:00AbbVie Sues Amgen Over Humira
08/02/201619:30:00CVS Drops Coverage of 2 Branded Biotech Drugs in Favor of Copies
08/02/201618:47:00CVS Drops Coverage of 2 Branded Biotech Drugs in Favor of Copies
08/02/201616:43:48Quarterly Report (10-q)
08/02/201608:40:00CVS Misses Sales Expectations as Pharmacy Business Softens
08/02/201608:22:00CVS Misses Sales Expectations as Pharmacy Business Softens
08/02/201607:05:57Current Report Filing (8-k)
08/02/201606:55:00CVS Health Reports Second Quarter Results
07/29/201610:11:00CVS Health to Increase Access to FDA-approved Nasal Naloxone...
07/25/201608:30:00CVS Health Makes Overdose-Reversal Drug Available Without A Prescription...
07/22/201612:00:00CVS Health Corporation To Hold Second Quarter 2016 Conference...

Cvs and other New York Stock Exchange stock quotes are delayed by at least 20 minutes.
All other stock price data is delayed by at least 15 minutes unless otherwise stated.
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Contact Us | Copyright 1999-2015 ADVFN PLC. | Privacy Policy | Investment Warning | Data accreditations | Investor Relations

ADVFNADVFN ItalyADVFN GermanyADVFN FranceADVFN BrazilADVFN JapanADVFN UKADVFN US noad